

OBSERVATIONS

Probing the Validity of the Probe-to-Bone Test in the Diagnosis of Osteomyelitis of the Foot in Diabetes

The ability to probe the base of a wound to periosteum or bone (the "probe-to-bone" test) is increasingly used to indicate the likelihood of underlying osteomyelitis. The original study (1) reported sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of 66, 85, 89, and 56%, respectively. However, this work has been criticized on the grounds of the high pretest probability of the disease (2), since the prevalence of osteomyelitis in the chosen sample (in-patients with clinically overt infection) was 66%. It follows that the usefulness of the test may be very different in less-selected populations. We have therefore determined the validity of the probe-to-bone test in a consecutive series of outpatients attending our own multidisciplinary service.

A total of 81 patients (with a total 104 foot ulcers) attended the clinic over a 5-week period in May–June 2005. Ulcers were probed by one of two specialist podiatrists following debridement. The diagnosis of osteomyelitis was determined by one of two expert diabetologists, who were blind to the results of the probe to bone test. The diagnosis of osteomyelitis was based in each case on the presence of clinical signs of infection (inflammation with or without serous or purulent discharge) in association with radiologic evidence of bone destruction with interruption of the cortex (either at presentation or at any stage over the ensuing 8 weeks), supported when necessary by magnetic resonance imaging and microbiologic analysis of deep tissue samples. Those who were diagnosed with osteomyelitis included those in whom the diagnosis had already been made at the time of probing and those in whom the diagnosis was made later. Nineteen (23.5%) patients were diagnosed with osteomyelitis complicating foot ulcers, in two of whom bone infection complicated two

separate nonadjacent ulcers. Three patients had two or more nonadjacent ulcers, of which only one was associated with osteomyelitis. A total of 14 patients had osteomyelitis complicating a single ulcer. A total of 21 ulcers (20.2% of 104) were associated with osteomyelitis. The probe-to-bone test was positive in 8 of these 21 ulcers and in 7 of 83 without associated bone infection (sensitivity 38%, specificity 91%). While the NPV was 85%, the PPV (the probability that a patient with a positive test would have osteomyelitis) was only 53%. It is possible that the calculation of both sensitivity and NPV might be in part explained by the fact that some cases of osteomyelitis may already have been responding to treatment at the time of probing, but this would not have affected the calculation of either the specificity or the PPV.

These data emphasize that the predictive value of a positive probe-to bone test in the original report was influenced by the high prevalence of osteomyelitis in the population studied. The prevalence of osteomyelitis in the present population was still high at 23.5% patients (20.2% ulcers) but was only approximately one-third of that in the earlier study, and the PPV was correspondingly lower. It is likely that the PPV would be lower still in patients managed in a less-specialized service.

ALISON SHONE, BSC
JACLYN BURNSIDE, BSC
SUSAN CHIPCHASE, BSC
FRAN GAME, FRCP
WILLIAM JEFFCOATE, MRCP

From the Department of Diabetes and Endocrinology, Foot Ulcer Trials Unit, City Hospital, Nottingham, U.K.

Address correspondence to William Jeffcoate, Foot Ulcer Trials Unit, Department of Diabetes and Endocrinology, City Hospital, Nottingham NG5 1PB, U.K. E-mail: wjeffcoate@futu.co.uk.

© 2006 by the American Diabetes Association.

References

1. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW: Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. *JAMA* 273:721–723, 1995
2. Wrobel JS, Connolly JE: Making the diagnosis of osteomyelitis: the role of prevalence. *J Am Podiatr Med Assoc* 88:337–343, 1998

An Exploratory Study Into the Effectiveness of a Combination of Traditional Chinese Herbs in the Management of Type 2 Diabetes

While a range of drugs are used to ameliorate the effects of type 2 diabetes and its complications, they tend to slow rather than stop the progression of the disease (1). Many herbs have been used traditionally by different cultures in the management of type 2 diabetes (2); however, in general there is little scientific evidence to support their efficacy. The aim of this project was to conduct a small-scale trial to examine the effects of a commercial combination of *Trichosanthes kirilowii*, *Polygonatum sibiricum*, *Dioscorea opposita*, *Panax ginseng*, and *Stevia rebaudiana* and chromium nicotinamide (Glucostat; Health World Limited, Eagle Farm, Australia) on type 2 diabetic subjects who are not yet taking orthodox medication.

Four male and six female subjects aged between 33 and 70 years who had been diagnosed with type 2 diabetes and were on a low glycemic diet participated in this study. They were administered a 3.2-g dose three times a day over a 90-day period. Fasting blood glucose (FBG) data were collected daily using handheld glucometers, and HbA_{1c} (A1C), cholesterol, and BMI were recorded at the start and end of the trial. This study was approved by the human ethics committee at the University of New England.

The mean FBG for all patients at the start of the study was 9.4 ± 1.1 mmol/l and ranged from 7.6 to 11.3 mmol/l. Nine patients responded to the treatment showing a significant, though moderate, decrease ($10 \pm 4\%$) in FBG; however, while A1C, cholesterol, and BMI also declined, this did not reach significance. When treatment stopped, FBG rose rapidly over 15–20 days to pretreatment concentrations; however, when treatment was resumed ($n = 5$) FBG again declined by 14.3% (range 8–21) over the following 6 weeks.

This herbal combination may have some benefit in the treatment of type 2 diabetes, particularly perhaps in the early stages of the disease. The effects, while significant, took time to become appar-

ent, and the herbal combination appears to slowly improve the FBG concentrations over a period of continuous use. Surprisingly, this effect was rapidly reversed when the treatment ceased, as blood glucose returned to pretreatment levels within 15–20 days. Those subjects who started to take the herbal remedy again after the withdrawal period showed a more rapid decline in their FBG concentrations than when they first started the treatment. It is unclear from this study whether the FBG would return to euglycemia over a longer period of time, but it appears that the rate of decline slows and may plateau before this was reached.

This study strongly suggests that this combination of traditional Chinese herbs, together with chromium, may be effective in improving glycemic control in people diagnosed with type 2 diabetes. The mechanism of action remains unclear and may be a combination of an increase in insulin responsiveness and glucose uptake. The relative importance of the individual component herbs is also unknown, and we are undertaking further studies to investigate this.

MECHELE COLLINS, BSC (HONS)
JAMES R. McFARLANE, PHD

From the School of Biological, Biomedical and Molecular Sciences, University of New England, Armidale, NSW, Australia.

Address correspondence to Dr. J.R. McFarlane, Physiology, University of New England, Armidale, NSW 2351. E-mail: jmcfarla@une.edu.au

© 2006 by the American Diabetes Association.

References

1. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM: Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. *Diabetes Care* 25:43–48, 2002
2. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS: Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care* 26:1277–1294, 2003

Severe Injection Site Reaction to Insulin Detemir

Insulin detemir is a new long-acting insulin analog. Though generally well tolerated, injection site reactions have been reported in 2% of insulin detemir users (1). Most commonly, these untoward reactions manifest as mild injection

site erythema or discomfort and seldom lead to discontinuation of the product. Herein, I report the case of a patient with a severe local reaction to insulin detemir necessitating its withdrawal.

A 37-year-old Caucasian woman with a 25-year history of type 1 diabetes was switched from NPH (Humulin N; Eli Lilly) to insulin detemir (Novo Nordisk) because of poor glycemic control characterized by undue variability of her blood glucose readings and an elevated HbA_{1c}. She was also being treated with insulin lispro (Eli Lilly), which she remained on. She had no previous history of injection site problems. With both the previous and the new insulin, she maintained the same proper injection technique and injected, as was her custom, into her abdominal wall.

The patient developed injection site problems within hours of her very first injection of insulin detemir with a characteristic and reproducible pattern occurring with all subsequent injections, ultimately necessitating withdrawal of the insulin within a few days of its institution. Within 6 h of an injection of insulin detemir she would develop a slightly raised, indurated, nonerythematous, minimally uncomfortable, nonpruritic, nontender lesion of ~3 cm. Over the subsequent 6 h, a lesion would expand in size reaching a diameter of 5–6 cm and become erythematous (without central sparing), warm, and moderately tender. Over the subsequent 12 h, a lesion would enlarge further, reaching a diameter of 10 cm, and become markedly indurated, hot, and extremely painful. Over the subsequent 12 h, a lesion would gradually and spontaneously resolve. No fever, chills, rigors, or sweats were experienced. Rotating her injection site around various parts of her abdomen was of no benefit, and a trial injection into the thigh resulted in the identical sequence of events. Insulin detemir was discontinued, and the patient reverted back to her former insulin with no further injection site problems.

Recently, a patient was described who was thought to have experienced a type III allergic reaction to insulin detemir (2); however, unlike the current patient, in this previous report, the lesions encountered were said to be “small” and only “slightly painful” as well as being nonerythematous. Whether the patient described in this case report reacted to the insulin detemir per se or one of its excipients is not known.

IAN R. BLUMER, MD, FRCP

From the Charles H. Best Diabetes Centre, Ajax, Ontario, Canada.

Address correspondence to Dr. Ian R. Blumer, 401-95 Bayly St. West, Ajax, ON, Canada. E-mail: ian@ianblumer.com.

© 2006 by the American Diabetes Association.

References

1. European Medicines Agency: Levemir European Public Assessment Report, Levemir-H-528-II-01 [article online], 2003. Available at <http://www.emea.eu.int/humandocs/Humans/EPAR/levemir/levemir.htm>. Accessed 19 December 2005
2. Darmon P, Castera V, Koepffel M, Petitjean C, Dutour A: Type III allergy to insulin detemir (Letter). *Diabetes Care* 28:2980, 2005

A Case of Fulminant Type 1 Diabetes Associated With Painless Thyroiditis

Type 1 diabetes is classified as type 1A and type 1B diabetes, which are considered to be caused by autoimmune and nonautoimmune (idiopathic) mechanisms, respectively (1). Fulminant type 1 diabetes is characterized by a rapid-onset diabetic ketoacidosis within a short period of time, normal to near-normal HbA_{1c} level at onset, and complete β -cell destruction and was originally reported as a subtype of type 1B diabetes (2). Recently, the involvement of viral infections has been suggested to be the triggering mechanism of fulminant type 1 diabetes (3,4). The involvement of T-cell autoimmunity in this disease, however, has also been reported (5–8). Thus, its etiology is still unclear. Here, we report a case of fulminant type 1 diabetes and painless thyroiditis that presented simultaneously.

A 47-year-old woman was admitted to our hospital in a diabetic ketoacidotic coma. She suffered from fatigue and fever 2 days before admission. One day before admission, she visited a clinic and was given drugs for the common cold. On the day of admission, however, she became comatose and was transferred to our emergency room. Her arterial blood pH was 6.9 and bicarbonate was 1.5 mmol/l. She had markedly increased levels of ketone bodies and serum potassium (7.6 mEq/l). Computed tomography of the brain showed no abnormal findings. After admission, she went into cardiac arrest

and was revived by cardiopulmonary resuscitation then treated in the intensive care unit. Her plasma glucose level was 56.3 mmol/l (1,013 mg/dl) and HbA_{1c} was 6.5%. Serum and urinary C-peptide levels were very low (0.2 ng/ml and 3 μg/day, respectively). There was no increase in C-peptide following intravenous administration of 1 mg glucagon. She had no islet-associated autoantibodies (GAD antibody, islet cell antibody, or insulinoma-associated antigen-2 [IA-2] antibody). Her serum amylase was 7,492 IU/l (normal range 30–130). She had elevated lipase and trypsin levels (52 units/l [0–49] and 2,860 ng/ml [100–550], respectively). These findings were consistent with fulminant type 1 diabetes, and she was treated with intensive insulin therapy. The patient had HLA-A24, which is reported to be associated with β-cell destruction (9), and had a homozygous HLA-DR9-DQ3 haplotype, which is strongly associated with autoimmune (type 1A) diabetes (10).

After admission, she had persistent sinus tachycardia. Thirteen days after admission, an echocardiogram revealed paroxysmal atrial fibrillation. At that time, her thyroid hormones were elevated (fT₃ 10.4 pg/ml, fT₄ 4.4 ng/dl) and thyroid-stimulating hormone was suppressed (<0.03 μU/ml). Thyroid-stimulating hormone receptor antibody was negative, and a 99m-Tc-labeled thyroid scan revealed a decreased uptake (Tc RI uptake ratio 0.275% [normal range 0.4–3.0]). Thyroid-stimulating hormone measured at the previous clinic 1 day before her admission was within normal limits. Thus, the onset of fulminant type 1 diabetes and painless thyroiditis appeared to be simultaneous.

Cases of fulminant type 1 diabetes with thyroid disease or with thyroid-related antibody were previously reported (11,12), and these cases were suggested to have immunogenetic characteristics. Painless thyroiditis is also generally considered to be an autoimmune disorder (13). This case also suggests participation of autoimmune mechanisms at the onset of fulminant type 1 diabetes. On the other hand, the association of a viral infection cannot be excluded because of preceding symptoms of infection. In a nationwide survey (14), fulminant diabetes comprises ~20% of Japanese type 1 diabetes with ketosis or ketoacidosis at the onset. This new subtype, however, might be a heterogeneous entity. This is the first case of fulminant type 1 diabetes associ-

ated with simultaneous painless thyroiditis. It is useful to follow such cases to elucidate fulminant type 1 diabetes etiology, and further study is required to clarify its entity.

AKIHIRO HAMASAKI, MD¹
 TAKAO TANIGUCHI, MD, PHD¹
 SHUNSUKE YAMANE, MD¹
 MIDORI IDA, MD¹
 MOTOZUMI OKAMOTO, MD, PHD¹
 YUICHIRO YAMADA, MD, PHD²
 NOBUYA INAGAKI, MD, PHD²
 YUTAKA SEINO, MD, PHD^{2,3}

From the ¹Department of Internal Medicine, Otsu Red Cross Hospital, Otsu, Shiga, Japan; the ²Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and the ³Kansai-Denryoku Hospital, Osaka, Japan.

Address correspondence to Akihiro Hamasaki, Department of Internal Medicine, Otsu Red Cross Hospital, 1-1-35, Nagara, Otsu, Shiga 520-8511 Japan. E-mail: hamasaki@metab.kuhp.kyoto-u.ac.jp.
 © 2006 by the American Diabetes Association.



References

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 21 (Suppl. 1):S5–S19, 1998
2. Imagawa A, Hanafusa T, Miyazawa J, Matsuzawa Y: A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. *N Engl J Med* 342:301–307, 2000
3. Imagawa A, Hanafusa T, Makino H, Miyagawa J-I, Juto P: High titres of IgA antibodies to enterovirus in fulminant type 1 diabetes. *Diabetologia* 48:290–293, 2005
4. Sekine N, Motokura T, Oki T, Umeda Y, Sasaki N, Hayashi M, Sato H, Fujita T, Kaneko T, Asano Y, Kikuchi K: Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. *JAMA* 285:1153–1154, 2001
5. Shimada A, Morimoto J, Kodama K, Oikawa Y, Irie J, Nakagawa Y, Narumi S, Saruta T: T-cell-mediated autoimmunity may be involved in fulminant type 1 diabetes (Letter). *Diabetes Care* 25:635–636, 2002
6. Shimada A, Oikawa Y, Shigihara T, Senda T, Kodama K: A case of fulminant type 1 diabetes with strong evidence of autoimmunity (Letter). *Diabetes Care* 25:1482–1483, 2002
7. Taniguchi T, Tanaka J, Seko S, Okazaki K, Okamoto M: Association of rapid-onset type 1 diabetes and clinical acute pancreatitis positive for autoantibodies to the exocrine pancreas (Letter). *Diabetes Care* 24:2156–2157, 2001
8. Taniguchi T, Okazaki K, Okamoto M,

- Seko S, Nagashima K, Yamada Y, Iwakura T, Seino Y: Autoantibodies against the exocrine pancreas in fulminant type 1 diabetes (Letter). *Pancreas* 30:191–192, 2005
9. Nakanishi K, Kobayashi T, Murase T, Nakatsuji T, Inoko H, Tsuji K, Kosaka K: Association of HLA-A24 with complete beta-cell destruction in IDDM. *Diabetes* 42:1086–1093, 1993
10. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H: Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. *Diabetologia* 48:294–300, 2005
11. Sakaue S, Nagata M, Wakabayashi O, Honda T, Yoshimura H, Yamaguchi T, Nishimura M: A case of fulminant type 1 diabetes with elevated rheumatoid factor and the temporal presence of thyroid-stimulating hormone receptor antibody (Letter). *Diabetes Care* 25:935–936, 2002
12. Miura Y, Suzuki A, Sato I, Kato Y, Oiso Y: A case of fulminant type 1 diabetes with Grave's disease (Letter). *Diabetes Care* 25:1894–1895, 2002
13. Dayan CM, Daniels GH: Chronic autoimmune thyroiditis. *N Engl J Med* 335:99–107, 1996
14. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shamada A, Shimizu I, Toyoda T, Maruyama T, Makino H: Fulminant type 1 diabetes: a nationwide survey in Japan. *Diabetes Care* 26:2345–2352, 2003

Recurrence of Diabetes After Diarrhea-Associated Hemolytic Uremic Syndrome

We read with interest the article by Suri et al. (1). In this article, we find a systematic review and meta-analysis of articles assessing diabetes during diarrhea-associated hemolytic uremic syndrome (D+HUS). The 21 included studies describe 49 children who developed diabetes during acute D+HUS. Long-term outcome was reported for 44 of 49 children: 13 of 34 survivors were left with persistent diabetes requiring insulin; 11 had persistent diabetes from the outset, while 2 redeveloped diabetes at 3 and 60 months after initial apparent recovery, respectively. The remaining 21 children were reported to have made a complete recovery from diabetes. However, follow-up was <12 months or not reported for these children.

We report a boy with relapse of diabetes after 82 months (6.8 years). This boy was hospitalized with severe D+HUS when he was 6 years old. During his stay in the intensive care unit, he developed hyperglycemia and was treated with insulin during 21 days. Eighty months later he presented with nose obstruction and headache and was diagnosed with sinusitis and polyposis nasi. He was treated with antibiotics, but the complaints persisted. Two months later, he was operated on (functional endoscopic sinus surgery), and postoperatively he received 2 mg beta-methason for 5 days. On the 5th day, he presented in the emergency department with polyuria, polydipsia, and lethargy. His glycemia was 1,500 mg/dl, and his blood pH was 7.33. He was intravenously treated with insulin, and the corticosteroids were ceased.

To differentiate between type 1 diabetes, glucocorticoid-induced diabetes, and post-HUS diabetes, some additional blood tests were done. Pancreatic autoantibodies, including islet cell, insulin, GAD65, and insulinoma-associated protein 2 antibodies were all negative. Insulin was 4 mU/l for a glycemia of 1,453 mg/dl. After normalization of the glycemia, the boy was started on a basal-bolus regimen with insulin aspart and insulin glargine. Twenty months later, he still requires insulin ($0.5 \text{ units} \cdot \text{kg}^{-1} \cdot \text{day}^{-1}$) and has an HbA_{1c} of 6.8%.

Our report in which we describe a relapse of diabetes after 82 months confirms the conclusion of Suri et al. that survivors of D+HUS should have aggressive surveillance and treatment of hyperglycemia, not only in the acute phase but also in the long run.

KRISTINA CASTEELS, MD, PHD

RITA VAN DAMME-LOMBAERTS, MD, PHD

From the Department of Pediatric Diabetes and Department of Pediatric Nephrology, University Hospital Gasthuisberg, Leuven, Belgium.

Address correspondence to Kristina Casteels, Department of Pediatric Diabetes, Pediatrics, UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. E-mail: kristina.casteels@uz.kuleuven.ac.be.

© 2006 by the American Diabetes Association.

References

1. Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX: Diabetes during diarrhea-associated haemolytic uremic syndrome. *Diabetes Care* 28:2556–2562, 2005

Maternal Age and Prevalence of Gestational Diabetes Mellitus

Maternal age is an established risk factor for gestational diabetes mellitus (GDM), but there is no consensus on the age above which there is significantly increased risk of GDM. In the literature, the lowest cutoff is ≥ 25 years, as recommended by the American Diabetes Association (1), but there are little data to support this recommendation. To determine the age threshold for increased risk of GDM, we have reviewed the prevalence of GDM, diagnosed by the World Health Organization criteria (2), in the singleton pregnancies managed in our department from 1998 to 2001. Data on maternal anthropometric parameters, parity status, and risk factors for GDM such as booking weight ≥ 70 kg, BMI $\geq 25 \text{ kg/m}^2$, chronic hypertension, significant medical history, and smoking, as well as risk factors identified in our population that included carrier of thalassemia trait (3) and HBsAg (4) and presence of iron deficiency anemia, which reduces the risk of GDM (5), were retrieved from a computerized database. The pregnancies were categorized according to maternal age, i.e., ≤ 20 years, 20–24 years, 25–29 years, 30–34 years, 35–39 years, and ≥ 40 years, for statistical analysis (SPSS for Windows version 11.0; SPSS, Chicago, IL) using the χ^2 test and Pearson's correlation. Multivariate analysis was used to determine the role of advancing maternal age adjusting for the other significant associated factors, and the adjusted relative risk and 95% CI was calculated for each age cohort with the 20–24 years cohort as the reference.

Of the 16,383 women managed in this period, 15,827 (96.6%) women continued their pregnancies beyond the first trimester, and the number (% of total) from the youngest to the oldest cohort were 318 (2.0%), 1,713 (10.8%), 4,446 (28.1%), 5,457 (34.5%), 3,279 (20.7%), and 614 (3.9%), respectively. There was a significant difference and positive correlation in the prevalence of GDM, increasing from 1.3, 2.5, 6.2, 10.3, 21.7, and 31.9%, respectively, from the youngest to the oldest cohort ($P < 0.001$). On multivariate analysis and adjusting for significant confounding factors that included weight ≥ 70 kg, BMI $\geq 25 \text{ kg/m}^2$, HBsAg

carrier, thalassemia trait carrier, significant medical history, multiparity, smoker, and absence of iron deficiency anemia, the risk for the older cohorts was significantly increased as follows: 25–29 years, 2.59 (1.84–3.67); 30–34 years, 4.38 (3.13–6.13); 35–39 years, 10.85 (7.72–15.25); and ≥ 40 years, 15.90 (10.62–23.80). There was no significant difference for the < 20 years cohort.

Our finding indicates that the risk of GDM becomes significantly and progressively increased from 25 years onwards. This supports the American Diabetes Association recommendation on the use of age ≥ 25 years as the cutoff for screening and the observation that maternal age ≥ 25 years is the factor most predictive of GDM (6). In clinical practice, maternal age of ≥ 25 years should be adopted instead of ≥ 35 years or 40 years as a risk factor for the development of GDM.

TERENCE T. LAO, MD^{1,2}

LAI-FONG HO, MSc³

BEN C.P. CHAN, MBBS^{1,3}

WING-CHEONG LEUNG, MBBS^{1,3}

From the ¹Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; the ²Research Centre of Heart, Brain, Hormone and Healthy Aging, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China; and the ³Department of Obstetrics and Gynaecology, Kwong Wah Hospital, Hong Kong, China.

Address correspondence to Prof. Terence Lao, Department of Obstetrics & Gynaecology, Queen Mary Hospital, 102 Pokfulam Rd., Hong Kong, People's Republic of China. E-mail: laotth@hku.hku.hk.

© 2006 by the American Diabetes Association.

References

1. American Diabetes Association: Gestational diabetes mellitus. *Diabetes Care* 27 (Suppl. 1): S88–S90, 2004
2. World Health Organization: *WHO Expert Committee on Diabetes Mellitus*. Geneva, World Health Org., 1980, p. 8–12 (Tech. Rep. Ser., no. 646)
3. Lao TT, Ho LF: α -Thalassaemia trait and gestational diabetes mellitus in Hong Kong. *Diabetologia* 44:966–971, 2001
4. Lao TT, Tse KY, Chan LY, Tam KF, Ho LF: HBsAg carrier status and the association between gestational diabetes with increased serum ferritin concentration in Chinese women. *Diabetes Care* 26:3011–3016, 2003
5. Lao TT, Ho LF: Impact of iron deficiency anemia on prevalence of gestational diabetes mellitus. *Diabetes Care* 27:650–656, 2004
6. Danilenko-Dixon DR, Van Winter JT,

Nelson RL, Ogburn PL: Universal versus selective gestational diabetes screening: application of 1997 American Diabetes Association recommendations. *Am J Obstet Gynecol* 181:798–802, 1999

Maternal Weight Gain Is Associated With Infant Insulin Concentrations During the 1st Year of Life

Since hyperinsulinemia tracks from childhood to adulthood and is associated with diabetes risk, identifying modifiable conditions during gestation that may impact insulin metabolism in offspring is important. We conducted a pilot study to investigate associations between maternal weight gain and infant insulin concentrations in an underserved population at high risk for diabetes. Mexican or Native American women with an infant <1 year of age provided written consent. Infant weight-for-age Z scores (WAZ) were calculated, and nonfasting plasma samples were analyzed for insulin by standard assay. Pearson's bivariate test was used to assess relationships between variables, and the unpaired *t* test was used to examine differences between means.

A total of 16 women (means \pm SE) 21.8 \pm 1.7 years) and their infants (6.4 \pm 0.9 months; 9 males and 7 females) completed the study, and medical records were available for 9 of these pairs. Based on combined self-reports and medical records, the mean prepregnancy weight was 71.5 \pm 4.0 kg, and the mean pregnancy weight gain was 10.7 \pm 2.4 kg. Infants were full term with birth weights ranging from 2,495 to 4,309 g (3,381 \pm 121.0 g); WAZ scores averaged 0.47 \pm 0.23. Blood insulin concentrations averaged 11.5 \pm 1.6 mU/L. Gestational weight gain was significantly correlated to infant insulin concentrations ($r = 0.662$; $P = 0.005$); however, for nondiabetic women with verifiable pregnancy weight gain ($n = 8$), this association was strengthened ($r = 0.763$, $P = 0.028$; Fig. 1). Infant insulin concentrations ($n = 16$) were not associated with birth weight, infant age, WAZ scores, prepregnancy weight, or maternal age.

These data show that maternal weight gain predicted infant insulin concentrations, explaining nearly 60% of the vari-




Figure 1—Correlation of maternal weight gain and infant insulin concentrations ($n = 8$ mother/infant pairs; $r = 0.763$, $P = 0.028$).

ance in these values. Diabetes during pregnancy has been associated with cord blood insulin and with insulin concentrations in adolescence (1), and in nondiabetic pregnancies, maternal weight gain was related to cord blood insulin in macrosomic neonates (2). Currently, a weight gain of 6.8–11.5 kg is recommended for overweight women, and obese women are advised to gain a minimum of 6.8 kg. In obese, nondiabetic women, minimal gestational weight gain (<5 kg) normalized obstetric outcomes, including hypertension, cesarean section, induction of labor, and macrosomia, and did not adversely affect fetal outcomes (3). Utilizing an emerging obstetric outcome, infant insulin concentrations, our preliminary data support the contention that gestational weight gain should be carefully considered in overweight populations at high risk for diabetes. Differential analyses of our data show that minimal gestational weight gain in the nondiabetic women (≤ 5 vs. > 5 kg) was associated with lower infant insulin concentrations (7.2 \pm 0.6 vs. 13.4 \pm 2.0 mU/L; $P = 0.013$). Together, the available data indicate that controlling weight gain during obese pregnancies may be advantageous and that more studies of this nature are warranted.

DONNA M. WINHAM, DRPH
CAROL S. JOHNSTON, PHD
KRISTEN M. RHODA, MS

From the Department of Nutrition, Arizona State University, Mesa, Arizona.

Address correspondence to Carol S. Johnston, PhD, Department of Nutrition, Arizona State University, 7001 East Williams Field Rd., Mesa, AZ 85212. E-mail: carol.johnston@asu.edu.

© 2006 by the American Diabetes Association.

References

1. Silverman BL, Rizzo TA, Cho NH, Metzger BE: Long-term effects of the intrauterine environment: the Northwestern University Diabetes in Pregnancy Center. *Diabetes Care* 21 (Suppl. 2):B142–B149, 1998
2. Hoegsberg B, Gruppuso PA, Coustan DR: Hyperinsulinemia in macrosomic infants of nondiabetic mothers. *Diabetes Care* 16: 32–36, 1993
3. Jensen DM, Ovesen P, Beck-Nielsen H, Molsted-Pedersen L, Sorensen B, Vinter C, Damm P: Gestational weight gain and pregnancy outcomes in 481 obese glucose-tolerant women. *Diabetes Care* 28: 2118–2122, 2005

Soluble Tumor Necrosis Factor Receptor 1 Is Strongly and Independently Associated With Serum Homocysteine in Nonobese Japanese Type 2 Diabetic Patients

The major clinical consequence of type 2 diabetes is mortality and morbidity from atherosclerotic vascular disease. With regards to the risk factors responsible for the evolution of atherosclerosis, Bierman (1) estimated that typical risk factors, including smoking, cholesterol, and blood pressure, can account for no more than 30% of excess cardiovascular risk factors in diabetic patients. Thus, other factors seem to play a key role in the progression of atherosclerosis in diabetes.

One potential factor is homocysteine. Homocysteine has been shown to contribute to the development of atherosclerosis in diabetic patients (2). Whereas the deficiencies of folate and vitamin B₁₂ lead to hyperhomocysteinemia, these deficiencies alone do not completely account for atherosclerotic changes induced by homocysteine in diabetic patients.

Tumor necrosis factor (TNF) is a potent candidate involved in the pathogenesis of atherosclerosis. Rauchhaus et al. (3) demonstrated that elevated soluble TNF receptor 1 (sTNF-R1) has shown to be predictive of cardiovascular mortality in patients with chronic heart failure. We

found that sTNF-R1 is independently associated with albuminuria in type 2 diabetic patients (4). To the best of our knowledge, however, it is not clear whether serum homocysteine is associated with TNF receptor in type 2 diabetic patients. The aim of the present study was therefore to investigate the relationships between serum homocysteine and TNF receptor in patients with type 2 diabetes.

Fifty nonobese Japanese type 2 diabetic patients were studied. Their BMI, HbA_{1c}, and serum creatinine were 22.6 ± 0.3 kg/m² (range 17.6–26.2), $7.8 \pm 0.2\%$ (5.5–12.3), and 0.70 ± 0.02 mg/dl (0.46–0.98), respectively. They had not been treated with insulin or any medications known to alter homocysteine level. In conjunction with homocysteine, systolic and diastolic blood pressure, HbA_{1c}, glucose, lipids, serum creatinine, TNF- α , sTNF-R1, and sTNF-R2 were measured after an overnight fast.

With univariate analysis, serum homocysteine was positively correlated with age ($r = 0.361$, $P = 0.012$), diabetes duration ($r = 0.292$, $P = 0.045$), serum creatinine ($r = 0.623$, $P < 0.001$), sTNF-R1 ($r = 0.415$, $P < 0.005$), and sTNF-R2 ($r = 0.371$, $P < 0.01$). Other variables including TNF- α , however, were not associated with homocysteine. Multiple regression analyses showed that serum homocysteine was independently associated with serum creatinine ($F = 20.1$) and sTNF-R1 ($F = 6.9$), which explained 49.3% of the variability of homocysteine. Thus, TNF system activity may be responsible for the evolution of atherosclerosis induced by homocysteine in nonobese Japanese type 2 diabetic patients.

ATARU TANIGUCHI, MD¹
MITSUO FUKUSHIMA, MD²
YOSHIKATSU NAKAI, MD³
MINAKO OHGUSHI, MD¹
AKIRA KUROE, MD¹
MICHIIRO OHYA, MD¹
YUTAKA SEINO, MD¹

From the ¹Division of Diabetes and Clinical Nutrition, Kansai-Denryoku Hospital, Osaka, Japan; the ²Department of Health Informatics Research, Translational Research Informatics Center, Kobe, Japan; and the ³Karasuma-Nakai Clinic, Kyoto, Japan.

Address correspondence to Ataru Taniguchi, MD, Division of Diabetes and Clinical Nutrition, Kansai-Denryoku Hospital, 2-1-7 Fukushima, Fukushima-ku, Osaka City, Osaka 553-0003, Japan. E-mail: taniguchi.ataru@a5.kepco.co.jp.

© 2006 by the American Diabetes Association.

References

1. Bierman EL: George Lyman Duff Memorial Lecture: Atherogenesis in diabetes. *Arterioscler Thromb* 12:647–656, 1992
2. Refsum H, Ueland M: Homocysteine and cardiovascular disease. *Annu Rev Med* 49: 31–62, 1998
3. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJS, Anker SD: Plasma cytokine parameters and mortality in patients with chronic heart failure. *Circulation* 102:3060–3067, 2000
4. Kawasaki Y, Taniguchi A, Fukuhishima M, Nakai Y, Kuroe A, Ohya M, Nagasaka S, Yamada Y, Inagaki N, Seino Y: Soluble TNF receptors and albuminuria in non-obese Japanese type 2 diabetic patients. *Horm Metab Res* 37:617–621, 2005

Phenformin-Induced Lactic Acidosis in an Older Diabetic Patient

A recurrent drama (phenformin and lactic acidosis)

Editor's note: The authors had the following statement in their letter to me, with which I agree, "Most physicians are aware of the risk of lactic acidosis in patients taking phenformin. However, this side effect is continuously observed because phenformin is still used in Italy, Brazil, and China. We believe that the publication of our observation in an important journal like Diabetes Care may help to prompt governments of these countries to ban phenformin, just like in the rest of the world. This is the only way to prevent further cases of this avoidable, unacceptable and life-threatening complication."

A 73-year-old man with diabetes presented with upper-abdominal pain and nausea. He also had a history of hypertension, a pace-maker implant, and peripheral arterial disease treated with amputation of his left leg. His therapy included ticlopidine, enalapril, omeprazole, and 2 mg glibenclamide/30 mg phenformin b.i.d. The patient was alert and cognitively intact. Blood pressure and heart rate were 120/70 mmHg and 70 bpm, respectively. Radiographs of the chest and abdomen and an abdominal ultrasound study were normal. Laboratory tests disclosed a severe lactic acidosis (pH 6.8, pCO₂ 14.1 mmHg, pO₂ 108 mmHg, HCO₃ 4.9 mmol/l, lactate 21 mmol/l, and anion gap 31 mmol/l). After phenformin discontinuation, the patient's conditions rapidly improved. He was treated with in-

travenous insulin and glucose (1) and discharged 7 days later in good condition.

This report confirms that phenformin-induced lactic acidosis (PLA) is still a public health problem (1,2). To our knowledge, phenformin is still used in Italy, China, and Brazil. In a Medline search, we found 12 cases that occurred in Italy between 1981 and 1998 (2). In two patients phenformin was even brought back into use soon after, thereby questioning the belief that PLA is adequately recognized (2). More importantly, according to data by Intercontinental Marketing Services (www.imshealth.com), 838,000 preparations of phenformin and a sulfonylurea have been sold in Italy between January and October 2005. Because PLA occurs in 1 of 4,000 patients (3) with a mortality rate of ~50%, these data raise worrying health care considerations. In fact, diabetic patients often have comorbid conditions known to favor PLA.

Phenformin was removed from the U.S. market in 1977, but, surprisingly, cases of patients who have been prescribed the drug abroad are continuously reported (1). Phenformin can also be illegally obtained online or through mail orders to replace metformin, which is more costly. Furthermore, herbal medicines containing phenformin are also consumed in developed countries. In February 2000, the Food and Drug Administration recalled five Chinese herbal medications containing phenformin (4), while Health Canada is currently warning consumers not to take "Shortclean," a phenformin-based Chinese "natural" medicine (5).

Phenformin can always be replaced by metformin, which should not be associated with a higher risk of lactic acidosis compared with nonbiguanide therapies (6). Despite most clinicians being aware of PLA, the only way for preventing further cases is to forbid phenformin in countries where it is still used.

FILIPPO LUCA FIMOGNARI, MD^{1,2}
RUGGERO PASTORELLI, MD¹
RAFFAELE ANTONELLI INCALZI, MD²

From the ¹Division of Internal Medicine, Leopoldo Parodi-Delfino Hospital, ASL Roma G, Colferro (Rome), Italy; and ²University Campus Biomedico of Rome, Rome, Italy.

Address correspondence to Dr. Filippo L. Fimognari, Centro per la Salute dell'Anziano (CeSA), University Campus Biomedico of Rome, Via dei Compositori 130, 00128, Rome, Italy. E-mail: filippo.fimognari@virgilio.it.

© 2006 by the American Diabetes Association.

specific treatments, it is accepted by all with a specialist interest in this field that the mainstay of emergency management is the immediate institution of effective offloading, preferably in a total contact cast. Offloading results in protection of the bones and joints of the foot, as well as amelioration of the underlying inflammatory process.

WILLIAM J. JEFFCOATE, MRCP¹
FRAN L. GAME, FRCP¹
DAVID G. ARMSTRONG, DPM, PHD²
PETER R. CAVANAGH, PHD³

From the ¹Department of Diabetes and Endocrinology, Nottingham City Hospital, Nottingham, U.K.; the ²Rosalind Franklin University of Medicine and Science, Dr. William M. Scholl College of Podiatric Medicine, Chicago, Illinois; and the ³Diabetic Foot Care Program, Cleveland Clinic, Cleveland, Ohio.

Address correspondence to William Jeffcoate, Foot Ulcer Trials Unit, Department of Diabetes and Endocrinology, City Hospital, Nottingham, NG5 1PB, UK. E-mail: wjeffcoate@futu.co.uk.

© 2006 by the American Diabetes Association.



References

1. Tan AL, Greenstein A, Jarrett SJ, McGonagle D: Acute neuropathic joint disease: a medical emergency? *Diabetes Care* 28: 2962–2964, 2005
2. Jude EB, Selby PL, Burgess J, Lillystone P, Mawer B, Page SR, Donohoe M, Foster AV, Edmonds ME, Boulton AJ: Pamidronate in diabetic Charcot arthropathy: a randomised placebo controlled trial. *Diabetologia* 44:2032–2037, 2001
3. Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM, Manto A, Caradonna P, Ghirlanda G: Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. *Diabetes Care* 28:1214–1215, 2005
4. Jeffcoate W: Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link (Review)? *Diabetologia* 47:1488–1492, 2004
5. Jeffcoate WJ, Game F, Cavanagh PR: The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. *Lancet* 366:2058–2061, 2005

Acute Neuropathic Joint Disease: A Medical Emergency?

Response to Jeffcoate et al.

We thank Jeffcoate et al. (1) for their comments on our article (2). To summarize, they agree that neuropathic joint disease (NJD) is in-

deed a medical emergency, but they disagree that bisphosphonates are of proven efficacy. One of the major problems for clinicians at the moment is the failure to recognize early NJD based on several considerations, including other possible diagnosis at presentation, the presence of pain, normal radiographs, and patients presenting to nonendocrinological specialists. Therefore, at the time of initiation of therapy, damage may already be well established and, furthermore, joint offloading with prolonged casting has several drawbacks (3).

It was not the intention of our article to convey the idea that the very early initiation of bisphosphonate therapy before radiographic damage would definitely halt disease. We agree with Jeffcoate et al. that further work needs to be done in this regard. However, given the data from trials in NJD, the safety profile and costs of bisphosphonate therapy, and ease of administration, it would seem reasonable to prescribe these.

It is interesting to note that bisphosphonates may have some structural modification properties in the more common garden variety of osteoarthritis (4) and also some evidence of symptom control (4,5). However, based on the magnetic resonance imaging (MRI) observations that the earliest stages of NJD is strikingly associated with bone edema, which is also a predictor of progressive osteoarthritis joint deterioration in other sites (6), besides the ankle and foot, then it would seem prudent that attempts to inhibit osteoclast function may be of use.

To summarize, we feel that the MRI features of early NJD will allow for early intervention, including those suggested by the authors, at a stage before irreversible joint damage to see whether ultimately progressive joint damage can be prevented. We feel that the MRI observations in early disease have broad implications for raising awareness of the potential for early NJD diagnosis and for monitoring potential therapies.

AI LYN TAN, MRCP^{1,2}
DENNIS MCGONAGLE, PHD, FRCP^{1,2}

From the ¹Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, U.K.; and the ²Department of Rheumatology, Calderdale Royal Hospital, Salterhebble, Halifax, U.K.

Address correspondence to Prof. Dennis McGonagle, Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, 2nd Floor, Chapeltown Road, Leeds, LS7 4SA, U.K. E-mail: d.g.mcgonagle@leeds.ac.uk.

© 2006 by the American Diabetes Association.



References

1. Jeffcoate WJ, Game FL, Armstrong DG, Cavanagh PR: Acute neuropathic joint disease: a medical emergency? (Letter). *Diabetes Care* 29:951–952, 2006
2. Tan AL, Greenstein A, Jarrett SJ, McGonagle D: Acute neuropathic joint disease: a medical emergency? *Diabetes Care* 28: 2962–2964, 2005
3. Eldor R, Raz I, Ben Yehuda A, Boulton AJ: New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. *Diabet Med* 21:1161–1173, 2004
4. Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F, Felson D, Peterfy C, Visser M, Harris TB, Wang BW, Kritchevsky SB: The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. *Arthritis Rheum* 50: 3516–3525, 2004
5. Spector TD, Conaghan PG, Buckland-Wright JC, Garnero P, Cline GA, Beary JF, Valent DJ, Meyer JM: Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. *Arthritis Res Ther* 7:R625–R633, 2005
6. Felson DT, McLaughlin S, Goggins J, LaValley MP, Gale ME, Totterman S, Li W, Hill C, Gale D: Bone marrow edema and its relation to progression of knee osteoarthritis. *Ann Intern Med* 139:330–336, 2003

Resistance to Insulin Therapy Among Patients and Providers: Results of the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) Study

Response to Peyrot et al.

The recent article by Peyrot et al. (1) concerning the attitudes of both patients and providers with respect to insulin therapy raises some potentially important issues about barriers to an important treatment in diabetes. However, their statement that “U.S. physicians were significantly more disposed to delay insulin therapy than physicians in all other countries . . .” (1) appears to contradict

differences in cited prescribing patterns between type 2 diabetic patients in America, Australia, and Europe. For example, results from the National Health and Nutrition Examination Survey 1999–2000 cohort (2,3) and a large western U.S. study (4) are consistent in finding that ~34% of type 2 diabetic patients on medication are using insulin. However, a more recent study (5) in the Canadian primary care setting reported only a 14% use of insulin, while two independent Australian studies (6,7) and our own results show an insulin prevalence of 16–18%. Studies in Denmark (8) and France (9) establish an insulin prescription rate of 24 and 17%, respectively. It therefore appears that physicians in U.S. are more likely to initiate insulin therapy for type 2 diabetic patients than their colleagues in other Western countries. The discrepancy between physicians' attitudes, as reported by Peyrot et al. (1), and actual practice may represent a lack of generalizability of their findings or that the such "attitudes" are not the principal determinants of prescribing behavior.

GEORGE PHILLIPOV, PHD
PATRICK J. PHILLIPS, FRCAP

From the Department of Endocrinology, The Queen Elizabeth Hospital, Woodville, South Australia.

Address correspondence to Dr. G. Phillipov, Department of Endocrinology, The Queen Elizabeth Hospital, Woodville, South Australia 5011. E-mail: george.phillipov@nwhs.sa.gov.au.

P.J.P. has been on an advisory board for and has received honoraria from Novo Nordisk and Aventis.

© 2006 by the American Diabetes Association.

5. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S: Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). *Diabetes Res Clin Pract* 70:90–97, 2005
6. Clifford RM, Davis WA, Cull CA, Bruce DG, Batty KT, Davis TM: Greater use of insulin by southern European compared with Anglo-Celt patients with type 2 diabetes: the Fremantle Diabetes Study. *Eur J Endocrinol* 151:579–586, 2004
7. Kemp TM, Barr EL, Zimmet PZ, Cameron AJ, Welborn TA, Colagiuri S, Phillips P, Shaw JE: Glucose, lipid, and blood pressure control in Australian adults with type 2 diabetes: the 1999–2000 AusDiab. *Diabetes Care* 28:1490–1492, 2005
8. Kristensen JK, Bro F, Sandbaek A, Dahler-Eriksen K, Lassen JF, Lauritzen T: HbA1c in an unselected population of 4438 people with type 2 diabetes in a Danish county. *Scand J Prim Health Care* 19:241–246, 2001
9. Detournay B, Raccach D, Cadilhac M, Eschwege E: Epidemiology and costs of diabetes treated with insulin in France. *Diabetes Metab* 31:3–18, 2005

mine physician prescribing behavior. Also important is the level of perceived need for insulin. The relevance of the attitude identified in our study depends explicitly on the level of perceived need for insulin treatment (delay of insulin "until it is absolutely essential"). If the need is perceived as greater in the U.S. than in other countries, U.S. physicians might be more likely to prescribe insulin even if are they have a higher threshold for making that choice. The level of perceived need might itself be a function of attitudes or it could be a result of actual differences in need, e.g., higher BMI, worse glycemic control, patient unwillingness to change lifestyles, etc.

We believe that finding out how all of these factors combine to influence physicians' insulin-prescribing behaviors would be a major contribution to the field. We hope that others will continue the study of this issue.

MARK PEYROT, PHD^{1,2}
RICHARD R. RUBIN, PHD^{2,3}

Resistance to Insulin Therapy Among Patients and Providers: Results of the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) Study

Response to Phillipov and Phillips

Phillipov and Phillips (1) suggest that our finding (2) that U.S. physicians were significantly more disposed to delay insulin therapy than were physicians in all other countries surveyed contradicted reports from other studies of the proportion of patients with type 2 diabetes taking insulin in the U.S., Australia, and some European countries. Phillipov and Phillips conclude that either our findings cannot be generalized or that attitudes are not the key determinant of prescribing behavior.

We thank Phillipov and Phillips for providing additional information regarding international differences in insulin-prescribing attitudes and behaviors. We agree that attitudes alone do not deter-

From the ¹Department of Sociology, Center for Social and Community Research, Loyola College, Baltimore, Maryland; the ²Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and the ³Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Address correspondence to Mark Peyrot, PhD, Center for Social and Community Research, Loyola College, 4501 North Charles St., Baltimore, MD 21210-2699. E-mail: mpeyrot@loyola.edu.

M.P. has served on an advisory board for and has received honoraria from Novo Nordisk and has received honoraria/consulting fees from MannKind. R.R.R. has served on advisory boards for and has received honoraria and consulting fees from Novo Nordisk.

© 2006 by the American Diabetes Association.

References

1. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinbreil L, the International Dawn Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. *Diabetes Care* 28:2673–2269, 2005
2. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. *Diabetes Care* 27:17–20, 2004
3. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA* 291:335–422, 2004
4. Harmel AP, Ryan D, Thompson R: Glycohemoglobin assessment program: glycated hemoglobin and epidemiologic variables in patients with type 2 diabetes. *Endocr Pract* 8:184–190, 2002

References

1. Phillipov G, Phillips PJ: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study (Letter). *Diabetes Care* 29:952–953, 2006
2. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinbreil L, the International Dawn Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. *Diabetes Care* 28:2673–2269, 2005

Beneficial Effects of a Dietary Approaches to Stop Hypertension Eating Plan on Features of the Metabolic Syndrome

Response to Azdbakht et al.

We read with interest the article by Azdbakht et al. (1), showing that a nutritional approach based on a Dietary Approaches to Stop Hypertension (DASH) diet reduced the prevalence of the syndrome by about one-third. This study adds to the mounting evidence that fighting metabolic and cardiovascular disease with diet is possible (2). As the DASH diet is very similar to the Mediterranean diet, these results confirm in the short term (6 months) previous findings obtained over a longer period of time (24 months) (3). The authors did a fine job obtaining such a significant weight loss (13 kg on the average in the weight-control arm and 15 kg on the average in the DASH arm), as the change in body weight expected with a program of intensive lifestyle changes may be less impressive (-6.7 ± 7.9 kg at 12 months) (3). Perhaps one would have expected a larger resolution of features of the metabolic syndrome in the weight-control arm (19% resolution). To give more strength to their work, the authors should also comment on some inconsistency in Table 2. Fasting blood glucose (FBG) was only 3 mg/dl at baseline in the control group (obviously a mistake); however, it seems difficult to imagine that the DASH diet increased FBG by 15 and 8 mg/dl on the average at 6 months (men and women), as in the RESULTS section the opposite is stated (obviously a mistake). As the table seems imprecise (the reason why values for men are reported as median and for women as mean is unclear), the authors should also check the huge SD of basal FBG. Lastly, there is an important thing missing: the starting and posttreatment quantity of energy consumed by participants is not reported, leaving the reader to assume that all subjects in both arms ate a diet with 500 kcal less than their caloric needs, without any check. The findings of Azdbakht et al. (1) confirm that diet is at least equivalent to drugs in reducing the prevalence of the metabolic syndrome (3–5).

KATHERINE ESPOSITO, MD, PHD
DARIO GIUGLIANO, MD, PHD

From the Division of Metabolic Diseases, University of Naples SUN, Naples, Italy.

Address correspondence to Dario Giugliano, MD, PhD, University of Naples SUN, Piazza L. Miraglia, 80138 Naples, Italy. E-mail: dario.giugliano@unina2.it.

© 2006 by the American Diabetes Association.

References

1. Azadbakht L, Mirmiran P, Esmailzadeh A, Azizi T, Azizi F: Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. *Diabetes Care* 28:2823–2831, 2005
2. Esposito K, Giugliano D: Diet and inflammation: a link to metabolic and cardiovascular diseases. *Eur Heart J* 27:15–20, 2006
3. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armineto M, D'Andrea F, Giugliano D: Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA* 292:1440–1446, 2004
4. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, Hesson LA, Osei SY, Kaplan R, Stunkard AJ: Randomized trial of lifestyle modification and pharmacotherapy for obesity. *N Engl J Med* 353:2111–2120, 2005
5. Orchard TJ, Tempres M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. *Ann Intern Med* 142:611–619, 2005

Beneficial Effects of a Dietary Approaches to Stop Hypertension Eating Plan on Features of the Metabolic Syndrome

Response to Esposito and Giugliano

We thank Esposito and Giugliano (1) for their attention to our study, in which we showed the beneficial effects of a Dietary Approaches to Stop Hypertension (DASH) eating pattern on components of the metabolic syn-

drome (2). DASH diet is similar to the Mediterranean diet; both have high levels of fiber and isoflavones and a large number of low-glycemic index foods such as vegetables and whole grains (3,4). We agree with Esposito and Giugliano that in the short term, our study (2) confirms the results reported by them previously (3). However, we discussed differences between DASH and Mediterranean diet in the CONCLUSIONS section of our study (2).

We reported a 13-kg weight reduction in the weight-reducing diet and a 15-kg reduction in the DASH diet (2). As it had been mentioned in the RESEARCH DESIGN AND METHODS section of our study, subjects on both weight-reducing diet and DASH diet ate 500 kcal less than their caloric needs. Despite intensive lifestyle changes in the study by Esposito et al. (3), patients did not consume a diet with 500 calories less than their needs. However, the patients reduced dietary caloric intake (if needed) by 170 kcal in the intervention group.

Regarding Esposito and Giugliano's expectation about the larger resolution of features of the metabolic syndrome in the weight-reducing diet, it should be kept in mind that the metabolic syndrome is a constellation of risk factors (high blood pressure, lipid abnormalities, and elevated blood glucose). Although the amount of weight reduction in the weight-reducing diet and DASH group in our study was not significantly different, the decrement of the prevalence of the metabolic syndrome in the DASH and the weight-reducing group was significantly different (-35 vs -19% , $P < 0.05$). Therefore, the nutrient content of the DASH diet may be important. The DASH diet has larger amounts of dairy and calcium that are inversely related to the metabolic syndrome and its components (5). Also, its sodium content is restricted, which could regulate blood pressure. Some studies (6) also have shown no significant effect of weight-reducing diet on some metabolic risks.

Unfortunately, Table 2 in our study (2) has some inconsistencies due to a typing error in the fasting blood glucose (FBG) values in women (the last row). The baseline FBG in the control group was actually 93 mg/dl and in the DASH group 91 and 86 mg/dl after 3 and 6 months, respectively. As it has been stated in Fig. 2, DASH diet decreased FBG by 15 and 8 mg/dl in men and women, respectively. By correcting the mentioned typing error, there would be a logical SD in FBG.

